Author(s)

Shixuan Peng

Corresponding Author

Shixuan Peng

ABSTRACT

The incidence of B-cell lymphoma is increasing year by year. The number of patients with diffuse large B-cell lymphoma over 75 years old in the United States is increasing at a rate of 1.4% per year. It had been ranked as the top 10th most common cancer-related cause of death. The growth factors that contribute to B-cell lymphoma have become central foci in clinical research. Zanubrutinib proves to be an effective drug in inhibiting BTK kinase. The phase I and phase II trial of Zanubrutinib was passed in 2014 and accepted accelerated approval at the beginning of 2020, December 2nd. Around the world, there are more than 20 clinical trials initiated and over 1000 patients receiving Zanubrutinib as a treatment to test its efficacy. After testing, the drug has been proven effective in treating the disease, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom Macroglobulinemia (WM). For instance, a clinical trial has illustrated an 84% overall response rate from zanubrutinib therapy in patients with MCL specifically and is currently recruiting more members on clinical research. In fact, for Asian patients undergoing clinical trials aging from 19-90, Zanubrutinib has proven to increase the AUC for as well. In this paper, some of the advancements of BTK inhibitor and several vital parameters, including mechanisms of various diseases and various clinical trials data in each of the drugs treating the several diseases, will be discussed throughout this report.

KEYWORDS

Zanubrutinib, Chronic lymphocytic leukemia (CLL), Waldenstrom Macroglobulinemia (WM), Mantle cell lymphoma (MCL)